Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc.RARE · Entity 4337 | Director | June 24, 2021 | June 28, 2021 |
| X4 Pharmaceuticals, IncXFOR · Entity 5638 | Director | June 10, 2024 | June 11, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ultragenyx Pharmaceutical Inc.
Report date June 24, 2021 · Filed June 28, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 66,849 |
Reported balance
After 2021-06-24 transaction · row 1
1 source rowRow 1 · 2021-06-24 · Grant · Acquired 2,145 · Balance 66,849 F1: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 24, 2022. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $93.20 · Expires 2031-06-24 | Direct | 4,125 |
Reported balance
After 2021-06-24 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-06-24 · Grant · Acquired 4,125 · Balance 4,125 F4: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 24, 2022. |
| Common StockSEC Table I · non-derivative | IndirectBy trust | 70,350 |
Reported balance
Holding disclosure · report date 2021-06-24 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 70,350 F2: These shares are held in a trust for the benefit of the Reporting Person's spouse and children. The Reporting Person's spouse and nephew are trustees of the trust. |
| Common StockSEC Table I · non-derivative | IndirectBy trust | 10,456 |
Reported balance
Holding disclosure · report date 2021-06-24 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 10,456 F3: These shares are held in a grantor retained annuity trust. The Reporting Person is the trustee of the trusts. |
Filing footnotes · ownership attribution and instrument terms
F1: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 24, 2022.
F2: These shares are held in a trust for the benefit of the Reporting Person's spouse and children. The Reporting Person's spouse and nephew are trustees of the trust.
F3: These shares are held in a grantor retained annuity trust. The Reporting Person is the trustee of the trusts.
F4: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 24, 2022.
X4 Pharmaceuticals, Inc
Report date June 10, 2024 · Filed June 11, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 96,667 |
Reported balance
After 2024-06-10 transaction · row 1
1 source rowRow 1 · 2024-06-10 · Grant · Acquired 45,000 · Balance 96,667 F1: Represents restricted stock units (RSUs) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units (RSUs) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
APPLIED GENETIC TECHNOLOGIES CORP
Report date November 30, 2022 · Filed December 01, 2022
Section 16 reporting ended · disclosed 2022-12-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-11-30 transaction · row 1
1 source rowRow 1 · 2022-11-30 · Other · Disposed 8,500 · Balance 0 F1: Includes 1,500 shares held by the Reporting Person's wife in a self-directed IRA. F2: At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for (1) $0.34 per share of common stock of the Issuer ("Common Stock"), without interest and less any applicable withholding taxes (the "Cash Consideration"); and (2) one contingent value right ("CVR") per share of Common Stock representing the right to receive potential milestone payments, currently estimated to be up to approximately $0.73 per CVR in the aggregate (without interest and less any applicable withholding taxes) (the Cash Consideration plus one CVR, collectively, as such amount may be increased in accordance with the terms of the Merger Agreement, the "Offer Price"). Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Offer Price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.40 · Expires 2028-09-20 | Direct | 0 |
Reported balance
After 2022-11-30 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-11-30 · Disposition to issuer · Disposed 25,000 · Balance 0 F3: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.90 · Expires 2028-11-15 | Direct | 0 |
Reported balance
After 2022-11-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-11-30 · Disposition to issuer · Disposed 10,000 · Balance 0 F3: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.02 · Expires 2029-12-04 | Direct | 0 |
Reported balance
After 2022-11-30 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-11-30 · Disposition to issuer · Disposed 10,000 · Balance 0 F3: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.72 · Expires 2030-12-16 | Direct | 0 |
Reported balance
After 2022-11-30 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-11-30 · Disposition to issuer · Disposed 12,000 · Balance 0 F3: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.17 · Expires 2031-11-30 | Direct | 0 |
Reported balance
After 2022-11-30 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-11-30 · Disposition to issuer · Disposed 14,000 · Balance 0 F3: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 1,500 shares held by the Reporting Person's wife in a self-directed IRA.
F2: At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for (1) $0.34 per share of common stock of the Issuer ("Common Stock"), without interest and less any applicable withholding taxes (the "Cash Consideration"); and (2) one contingent value right ("CVR") per share of Common Stock representing the right to receive potential milestone payments, currently estimated to be up to approximately $0.73 per CVR in the aggregate (without interest and less any applicable withholding taxes) (the Cash Consideration plus one CVR, collectively, as such amount may be increased in accordance with the terms of the Merger Agreement, the "Offer Price"). Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Offer Price.
F3: At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 05, 2016 Filed Dec 5, 2016 22:39 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $21.00 | $0.00 |
DisclosureSEC source: 0001562180-16-003674 · primarydocument.xml · derivative · entry 4 Aliski William · CIK 0001598426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,500 Underlying: Common Stock · 6,000 shares Expires 2024-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/3 of the shares initially subject to the option vested one year from January 30, 2014 and then 1/36 of the shares initially subject to the option began vesting monthly thereafter. Read SEC document |
| December 05, 2016 Filed Dec 5, 2016 22:39 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 2,000 | $78.70 | $157,400.00 |
DisclosureSEC source: 0001562180-16-003674 · primarydocument.xml · nonDerivative · entry 3 Aliski William · CIK 0001598426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,985 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.60 to $78.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 05, 2016 Filed Dec 5, 2016 22:39 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 4,000 | $77.94 | $311,760.00 |
DisclosureSEC source: 0001562180-16-003674 · primarydocument.xml · nonDerivative · entry 2 Aliski William · CIK 0001598426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,985 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.60 to $78.51 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 05, 2016 Filed Dec 5, 2016 22:39 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Exercise / conversionCommon Stock | 6,000 | $21.00 | $126,000.00 |
DisclosureSEC source: 0001562180-16-003674 · primarydocument.xml · nonDerivative · entry 1 Aliski William · CIK 0001598426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,985 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 27, 2015 Filed Oct 9, 2018 20:36 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 400 | $122.58 | $49,032.00 |
DisclosureSEC source: 0001209191-18-054531 · doc4.xml · nonDerivative · entry 4 Aliski William · CIK 0001598426 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By trust Disclosed balance after: 109,000 F2 · ownership.nature: These shares are held in a trust for the benefit of the reporting person's spouse and children. The reporting person's spouse and nephew are trustees of the trust. Read SEC document |
| May 27, 2015 Filed Oct 9, 2018 20:36 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 2,000 | $85.94 | $171,880.00 |
DisclosureSEC source: 0001209191-18-054531 · doc4.xml · nonDerivative · entry 3 Aliski William · CIK 0001598426 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By trust Disclosed balance after: 109,400 F2 · ownership.nature: These shares are held in a trust for the benefit of the reporting person's spouse and children. The reporting person's spouse and nephew are trustees of the trust. Read SEC document |
| May 12, 2015 Filed Oct 9, 2018 20:36 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 10,500 | $68.65 | $720,825.00 |
DisclosureSEC source: 0001209191-18-054531 · doc4.xml · nonDerivative · entry 2 Aliski William · CIK 0001598426 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By trust Disclosed balance after: 111,400 F2 · ownership.nature: These shares are held in a trust for the benefit of the reporting person's spouse and children. The reporting person's spouse and nephew are trustees of the trust. Read SEC document |
| February 05, 2014 Filed Oct 9, 2018 20:36 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | ConversionSeries A Preferred Stock · Derivative | 266,343 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-054531 · doc4.xml · derivative · entry 8 Aliski William · CIK 0001598426 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By trust Disclosed balance after: 0 Underlying: Common Stock · 84,970 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock was convertible into Common Stock at any time and automatically converted into Common Stock on a 1-for-3.1345 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F4 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock was convertible into Common Stock at any time and automatically converted into Common Stock on a 1-for-3.1345 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F4 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock was convertible into Common Stock at any time and automatically converted into Common Stock on a 1-for-3.1345 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F5 · derivative.underlying_shares: The number of underlying shares of Common Stock reported in Column 7 reflects the automatic conversion of shares of Series A Preferred Stock into Common Stock on a 1-for-3.1345 basis immediately prior to the closing of the Issuer's initial public offering. F2 · ownership.nature: These shares are held in a trust for the benefit of the reporting person's spouse and children. The reporting person's spouse and nephew are trustees of the trust. Read SEC document |
| February 05, 2014 Filed Oct 9, 2018 20:36 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | ConversionCommon Stock | 84,970 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-054531 · doc4.xml · nonDerivative · entry 1 Aliski William · CIK 0001598426 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By trust Disclosed balance after: 121,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The number of shares of Common Stock reported reflects the automatic conversion of shares of Series A Preferred Stock into Common Stock on a 1-for-3.1345 basis immediately prior to the closing of the Issuer's initial public offering. F2 · ownership.nature: These shares are held in a trust for the benefit of the reporting person's spouse and children. The reporting person's spouse and nephew are trustees of the trust. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.